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956Clinical Significance of Serum Hepcidin Levels on Early
Infectious Complications in Allogeneic Hematopoietic
Stem Cell Transplantation
Junya Kanda,1,3 Chisaki Mizumoto,1 Hiroshi Kawabata,1 Tatsuo Ichinohe,1
Hideyuki Tsuchida,2 Naohisa Tomosugi,2 Keitaro Matsuo,3,4 Kouhei Yamashita,1
Tadakazu Kondo,1 Takayuki Ishikawa,1 Takashi Uchiyama1The association of iron overload with complications of allogeneic hematopoietic stem cell transplantation
(HSCT) has been suggested in previous studies. Because hepcidin plays a central role in the regulation of
iron homeostasis, we analyzed the association between pretransplant serum hepcidin-25 levels and early
infectious complications after allogeneic HSCT. We studied 55 consecutive adult patients with a median age
of 47 years (range: 20–64 years) who underwent allogeneic HSCT for hematologic malignancies at our insti-
tution. Thirty-two patients had myelogenous malignancies; the remaining 23 had lymphogenous malignancies.
The median pretransplant serum hepcidin level of patients in the study was 21.6 ng/mL (range: 1.4–371 ng/mL),
which was comparable to that of healthy volunteers (median: 19.1 ng/mL [range: 2.3–37 ng/mL]; n5 17). When
cumulative incidences of documented bacterial and cytomegalovirus (CMV) infections at day 100 were com-
pared according to pretransplant hepcidin-25 levels, the incidence of bacterial, but not CMV, infection, was sig-
nificantly higher in the high-hepcidin group ($50 ng/mL; n5 17) than in the low-hepcidin group (\50 ng/mL;
n5 38) (65% [95% confidence interval, 38%–82%] versus 11% [3%–23%]; P\.001). This finding was confirmed
by multivariate Cox analysis adjusted for confounders, including pretransplant ferritin and C-reactive protein
(CRP) levels. No fungal infection was documented in either group. These results suggest that the pretransplant
serum hepcidin-25 level may be a useful marker for predicting the risk of early bacterial complications after
allogeneic HSCT. Larger prospective studies are, however, warranted to confirm our findings.
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Allogeneic hematopoietic stem cell transplantation
(HSCT) has been widely performed as a potentially
curative treatment for intractable hematologic malig-
nancies with conventional chemotherapy. However,
despite recent advances in the treatment of infectious1Department of Hematology and Oncology, Graduate
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6/j.bbmt.2009.04.008diseases and conditioning regimens for transplanta-
tion, treatment-related complications remain a major
problem. Therefore, it is particularly important to
identify a good biomarker that can predict treat-
ment-related complications before transplantation.
A recently accumulated body of evidence suggests
that iron overload is associated with adverse clinical
outcomes in HSCT [1-10]. Armand et al. [2] showed
that a high pretransplant serum ferritin level was
strongly associated with lower overall and disease-
free survival (OS, DFS) in patients with allogeneic
HSCT that was performed as a treatment for acute
leukemia and myelodysplastic syndrome (MDS).
Other studies have shown that pretransplant iron over-
load in autologous or allogeneic HSCT was a risk
factor associated with posttransplant complications,
such as mucositis, bacterial, and fungal infection, and
hepatic veno-occlusive disease (VOD) [3-6,8-11].
Hepcidin, first identified in human blood and urine
as an antimicrobial small peptide [12,13], is now con-
sidered to be a central molecule that regulates ironme-
tabolism. Hepcidin decreases iron absorption from the
intestine and blocks its release from iron stores by
Biol Blood Marrow Transplant 15:956-962, 2009 957Significance of Hepcidin in Transplantationdownregulating the expression of the cellular iron ex-
porter, ferroportin [14,15]. Hepatic expression of hep-
cidin can be upregulated by iron loading [16,17] as well
as by inflammatory stimuli such as interleukin-6 (IL-6)
[18]. Therefore, we hypothesized that serum hepcidin
level could be a useful predictor of iron overload and
inflammatory condition prior toHSCT.Here, we per-
formed a single-center retrospective study at our insti-
tution to evaluate the significance of serum hepcidin
levels as a predictor of early treatment-related compli-
cations after allogeneic HSCT with special reference
to infectious complications.PATIENTS AND METHODS
Study Population
The study population comprised 66 consecutive
adult patients who underwent allogeneic HSCT for
the treatment of hematologic malignancies at Kyoto
University Hospital from July 2006 to September
2008. A total of 55 patients, excluding those who had
received prior transplantations within 1 year or who
had any active infections before the current transplan-
tation, were included in the analysis. This study was
approved by the Ethics Committee of Kyoto Univer-
sity Graduate School and the Faculty of Medicine.
Written informed consent was obtained from all
patients.
Serum Analysis
Before the administration of conditioning regi-
mens, serum samples were obtained at around 8:00
am, allocated in tubes, and stored at –80C until anal-
ysis. The levels of serum hepcidin-25 (themain form of
active hepcidin peptide) were quantified using a liquid
chromatography-tandem mass spectrometry-based
assay system following the method described by
Murao et al. [19]. Other serum parameters were mea-
sured using standard laboratory techniques.
Prophylaxis, Monitoring, and Diagnosis of
Infection
The patients were isolated in a single room equip-
ped with a high-efficiency particulate air filter (HEPA)
system from 1 day before transplantation until at least
4 weeks after transplantation. No bacterial prophylaxis
was prescribed for the patients according to our insti-
tutional protocols [20]. Trimethoprim-sulfamethoxa-
zole (160 mg/day [trimethoprim], 3 times a week) was
administered as prophylactic therapy for Pneumocystis
jirovecii pneumonia from the day of admission until
the day of transplantation and restarted after the
day of neutrophil engraftment. All patients received flu-
conazole (200 or 400 mg/day) and acyclovir (1000 mg/
day) prophylaxis from the period of conditioning until30 days after transplantation. After the first 30 days,
the patients received fluconazole at a dose of
100 mg/day until at least 100 days after transplanta-
tion. The administration of acyclovir (400 mg/day)
was continued when patients received steroid therapy
for acute graft-versus-host disease (aGVHD). For
each febrile episode, 1 or 2 sets of blood samples
were cultured, and the cultures of specimens other
than blood and imaging examinations were performed
according to clinical judgment. The occurrence of cy-
tomegalovirus (CMV) infection was closely monitored
by CMV pp65 antigenemia testing with C10/C11
monoclonal antibodies (mAbs) from the day after neu-
trophil engraftment until at least 100 days after trans-
plantation. Documented bacterial infection included
any incidence of bloodstream infection or any other
bacterial infection. Bloodstream infection was diag-
nosed if at least 1 of the following criteria was met:
(1) blood culture obtained during a febrile episode
was positive, at least once, for bacterial organisms
not considered to be common skin contaminants; (2)
blood culture obtained during a febrile episode was
positive for the same common skin contaminant on
separate occasions within 72 hours; (3) blood culture
was positive, at least once, for a common skin contam-
inant, and the patient was diagnosed with septicemia,
including hypotension (systolic blood pressure, \90
mmHg) and abnormal coagulopathy. Infections other
than bloodstream infection were diagnosed if the fol-
lowing criteria were met: (1) bacterial organisms
were observed from specimens such as sputum, urine,
and stool at least on 2 occasions, and (2) the patient
showed symptoms of infection corresponding to those
specimens. Clositridium difficile enterocolitis was ex-
cluded from the analysis, because this disease is
toxin-mediated, and cannot be prevented by adminis-
tration of common bacterial prophylactic agents such
as fluoroquinolones, even if patients with a high risk
of bacterial infection can be identified by using a puta-
tive biomarker. CMV infection was defined as positive
if either C10 or C11 antigenemia assay showed at least
2 positive cells per 150,000 leukocytes. Invasive fungal
infection was diagnosed according to the criteria of the
European Organization for Research and Treatment
of Cancer/Invasive Fungal Infections Cooperative
Group and the National Institute of Allergy and Infec-
tious Diseases Mycoses Study Group [21].Statistical Analysis
Endpoints included cumulative incidences of
documented bacterial infection, fungal infection,
CMV infection, and infection-related mortality, and
OS within 100 days post transplantation. Patient
and transplant characteristics between 2 groups
were compared using the Mann-Whitney U-test or
c2 analysis, as appropriate. The day of neutrophil
Table 1. Characteristics of Patients and Transplants
Variables
Hepcidin,
Low (<50 ng/mL)
n5 38
Hepcidin,
High ($50 ng/mL)
n5 17 P Value
Age at transplant
Median age (range) 47.5 (23–64) 47 (20–63) .750
Sex .171
Male 21 (55%) 6 (35%)
Female 17 (45%) 11 (65%)
Disease .612
Myeloid malignancies 23 (61%) 9 (53%)
AML 15 8
MDS/MPD 8 1
Lymphoid malignancies 15 (39%) 8 (47%)
ALL 4 4
ATL 4 1
HL 1 0
NHL 6 3
Risk of disease .051
Standard 22 (58%) 5 (29%)
High 16 (42%) 12 (71%)
Conditioning regimen .545
Myeloablative intensity 19 (50%) 10 (59%)
Reduced intensity 19 (50%) 7 (41%)
Prophylaxis against GVHD .663
Cyclosporine-based 5 (13%) 3 (18%)
Tacrolimus-based 33 (87%) 14 (82%)
Type of donor .181
Related donor
HLA*-matched 10 (26%) 3 (18%)
HLA-mismatched 3 (8%) 1 (6%)
Unrelated donor
HLA-matched 18 (47%) 5 (29%)
HLA-mismatched 7 (18%) 8 (47%)
Source of stem cells .259
Bone marrow 29 (76%) 10 (59%)
Peripheral blood 1 (3%) 0 (0%)
Cord blood 8 (21%) 7 (41%)
Serum ferritin (mg/dL)
mean (±SD) 664 (±796) 1551 (±993) <.001
CRP (mg/dL)
mean (±SD) 0.36 (±0.68) 0.70 (±1.63) .176
Reticulocyte (109/L)
mean (±SD) 63.7 (±40.2) 64.0 (±42.2) .979
AML indicates acute myelogenous leukemia; MDS/MPD, myelodysplastic
syndrome and myeloproliferative disorders; ALL, acute lymphoblastic
leukemia; ATL, acute T cell leukemia/lymphoma; HL, Hodgkin lym-
phoma; NHL, non-Hodgkin lymphoma; GVHD, graft-versus-host dis-
ease; Cyclosporine-based, cyclosporine with or without other agents;
Tacrolimus-based, tacrolimus with or without other agents; HLA, human
leukocyte antigen; CRP, C-reactive protein.
Data are counts of individuals unless specified otherwise.
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days when the absolute neutrophil count (ANC) ex-
ceeded 500/mL. The day of neutrophil engraftment
between 2 groups was compared by using the
Mann-Whitney U-test. To eliminate the effect of
competing risk, the cumulative incidences were as-
sessed using methods described elsewhere [22]. The
competing event in the cumulative incidence analyses
was defined as death without an event of interest
within 100 days post transplantation. OS was esti-
mated using Kaplan-Meier methods. Infection-
related death was defined as death associated with
any infection within 100 days after transplantation.
Standard risk disease was defined as complete remis-
sion (CR) in cases of acute myelogenous leukemia
(AML), acute lymphoblastic leukemia (ALL), adult
T cell leukemia/lymphoma (ATL), Hodgkin lym-
phoma (HL), non-Hodgkin lymphoma (NHL), and
untreated or CR in MDS and myeloproliferative dis-
order (MPD). High-risk disease was defined as sta-
tuses other than CR in AML, ALL, ATL, HL, and
NHL and in MDS and MPD after treatment. The
Cox proportional-hazard model was applied to assess
the effect of factors that potentially affected the study
endpoints. The following items were added as con-
founders: recipient’s sex (male or female), recipient’s
age (\50 or $50 years), diagnosis (myelogenous or
lymphogenous malignancies), risk of disease (stan-
dard or high risk), conditioning regimen (reduced
or myeloablative intensity [RIC, MA]), type of donor
(related or unrelated donor), reticulocyte count
(\60 109 or $60 109/L), ferritin level (\1000
or $1000 mg/dL), and C-reactive protein (CRP)
level (\0.3 or $0.3 mg/dL). The cutoff points for re-
ticulocyte count and the ferritin and CRP levels were
chosen such that we could make optimal use of the
information with a proviso that the smaller group
contained at least 30% of patients. P values of\ .05
were considered statistically significant. All analyses
were conducted using STATA software version 10
(STATA Corp., College Station, TX).*HLA compatibility was defined according to the results of serologic or
low-resolution molecular typing for HLA-A, -B, and -DR antigens.RESULTS
Characteristics of Patients and Transplants
Characteristics of patients and transplants are
shown in Table 1. The median age of patients was 47
years (range: 20–64 years). The primary disease in
these patients was as follows: AML in 23, MDS/
MPD in 9, ALL in 8, NHL in 9, HL in 1, and ATL
in 5. The risk of diseases was standard in 27 and high
in 28 patients. Nearly half of the patients (n5 26) re-
ceived a RIC regimen. The stem cell sources used
were bone marrow (BM) in 39, peripheral blood (PB)
in 1, and cord blood (CB) in 15 patients. The median
pretransplant serum hepcidin level was 21.6 ng/mL(range: 1.4–371 ng/mL), which was comparable to
that of healthy volunteers (median: 19.1 ng/mL [range:
2.3–37 ng/mL]; n5 17) [23]. Because the lower hepci-
din level of the third tertile among the patients in
this study was 49.1 ng/mL, we set a cutoff hepcidin
level of 50 ng/mL for practical use to divide the pa-
tients into low- and high-hepcidin groups (n5 17
and 38, respectively). There was no difference in pa-
tient and transplant characteristics between the low-
and high-hepcidin groups, except for serum ferritin
levels (P\ .001).
Figure 1. The cumulative incidences of documented bacterial infection
(A) and cytomegalovirus (CMV) infection (B) at 100 days after stem cell
transplantation. Solid black line, the low-hepcidin group (\50 ng/mL);
solid gray line, the high-hepcidin group ($50 ng/mL); CI, confidence in-
terval. CMV infection was not assessable in 2 patients because of early
death before neutrophil engraftment.
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There was no significant difference between the
days of neutrophil engraftment of the low- and
high-hepcidin groups (median day: 21 [range: 14–99]
and median day: 22.5 [range: 12–53], respectively,
P5 .54). A total of 16 episodes of bacterial infections
were documented; these included 15 episodes of
bloodstream infections and 1 episode of pneumonia.
No patient experienced more than 1 episode of bacte-
rial infection within 100 days after transplantation.
The documented bacterial organisms are listed in
Table 2. The main organisms were Gram-negative ba-
cilli in both the low- and high-hepcidin groups. In the
antimicrobial-susceptibility tests, 12 of the 13 Gram-
negative isolates were sensitive to fluoroquinolone.
We documented 2 bacterial infections in the late pe-
riod of transplantation; 1 patient showed infection at
day 89 after transplantation, which was attributed to
delayed neutrophil engraftment, and another patient
showed infection at day 68, when the neutrophil
counts had temporarily decreased. The cumulative in-
cidences of the documented bacterial infection in the
low- and high-hepcidin groups were 11% (95% confi-
dence interval [CI], 3%–23%) and 65% (95% CI,
38%–82%), respectively (Figure 1A). In the low-hep-
cidin group, the cumulative incidence of bacterial in-
fection was lower in patients with a hepcidin level of
\25 ng/mL than in those with a hepcidin level ranging
from $25 to\50 ng/mL (10% [95% CI, 2%–23%]
versus 17%, [95% CI, 1%–52%]). Univariate analysis
of various potential confounders showed that high
hepcidin level was the only factor that affected the
cumulative incidence of documented bacterial infec-
tion (hazard ratio [HR], 8.98; 95% CI, 2.82–28.57;
P\ .001) (Table 3). To exclude the effect of other con-
founders, the significance of high hepcidin level was
assessed in the stratified category of each confounder
(eg, in either the high- or low-ferritin group); we noted
consistently high HRs in the high-hepcidin group in
each stratified category (data not shown). We also
found that hepcidin had a significant impact on the pa-
tients, excluding the patients in other specific cate-
gories, such as those who received a CB transplant or
those who underwent a transplant from an unrelatedTable 2. Documented Bacterial Organisms within 100 Days
after Stem Cell Transplantations
Category
Hepcidin, Low
(<50 ng/mL) n5 38
Hepcidin, High
($50 ng/mL) n5 17
Gram-positive
cocci (n)
Staphylococcus epidermidis (1) Enterococcus faecium (2)
Gram-negative
bacilli (n)
Klebsiella pneumoniae (2) Klebsiella pneumoniae (3)
Enterobacter cloacae (1) Escherichia coli (3)
Prevotella intermedia (1) Pseudomonas aeruginosa (2)
Klebsiella oxytoca (1)
P. intermedia was detected in the sputum of 1 patient with pneumonia.
Other organisms were detected in blood culture bottles.HLA-mismatched donor (data not shown). Further-
more, the significant effect of hepcidin persisted even
after the adjustment for confounders in multivariate
analysis (HR, 28.46; 95% CI, 2.51–323.34; P5 .007)
(Table 3). Even when the variables were treated as con-
tinuous instead of categoric, the significant effect of
hepcidin persisted (HR, 1.01; 95% CI, 1.00-1.01;
P5 .001).Other Transplant-Related Complications and
Mortality
The cumulative incidences of CMV infection in
the low- and high-hepcidin group were 49% (95%
CI, 32%–64%) and 45% (95% CI, 20%–67%), re-
spectively (Figure 1B); univariate and multivariate
analyses showed no significant difference between
the 2 groups (Table 3). All CMV infections were
well treated by the administration of ganciclovir or fo-
scarnet. No fungal infection was documented. There-
fore, all infection-related deaths were attributed to
bacterial infection. The cumulative incidence of infec-
tion-related mortality in the low-hepcidin group
was 3% (95% CI, 0.2%–12%), whereas that in the
high-hepcidin group was 6% (95% CI, 0.4%–24%),
Table 3. Univariate andMultivariate Analyses of Documented Bacterial Infection, CMV Infection, andOverall Survival at 100Days
after Stem Cell Transplantations
Number
Univariate Analysis Multivariate Analysis
HR (95% CI) P Value HR (95% CI) P Value
1) Documented bacterial infection
Hepcidin, low (<50 ng/mL) 5/38 1 – 1 –
Hepcidin, high ($50 ng/mL) 11/17 8.98 (2.82–28.57) <.001 28.46 (2.51–323.34) .007
2) CMV antigenemia (C10 or C11 $2)
Hepcidin, low (<50 ng/mL) 18/37 1 – 1 –
Hepcidin, high ($50 ng/mL) 7/16 0.97 (0.40–2.32) .939 0.63 (0.16–2.49) .511
3) Overall survival
Hepcidin, low (<50 ng/mL) 36/38 1 – – –
Hepcidin, high ($50 ng/mL) 14/17 3.60 (0.60–21.56) .161 – –
CMV indicates cytomegalovirus; CI, confidence interval.
Hazard ratios (HRs) in multivariate analysis were adjusted for recipient’s sex (male or female), recipient’s age (<50 or $50 years), diagnosis (myelo-
genous or lymphoid malignancies), risk of disease (standard or high risk), conditioning regimen (reduced or myeloablative intensity), type of donor
(related or unrelated donor), reticulocyte count (<60  109 or $60  109/L), ferritin level (<1000 or $1000 mg/dL), and C-reactive protein (CRP)
level (<0.3 or $0.3 mg/dL). Overall survival was not analyzed in the multivariate model because of the low incidence of death.
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OS at 100 days after transplantation in the low-
and high-hepcidin groups was 95% (95% CI, 81%–
99%) and 82% (95% CI, 55%–94%), respectively
(Figure 2). No significant difference in OS was
observed (Table 3).DISCUSSION
In our cohort of patients who underwent alloge-
neic HSCT for hematologic malignancies, we found
a significant association between the pretransplant se-
rum hepcidin levels and the cumulative incidence of
documented bacterial infection. To our knowledge,
this is the first study that has evaluated the clinical sig-
nificance of serum hepcidin levels in predicting trans-
plant-related complications; the findings suggest that
the pretransplant serum hepcidin level can be used as
a good pretransplant biomarker to predict bacterial in-
fection in a patient scheduled for HSCT.Figure 2. Kaplan-Meier estimate of OS at 100 days after stem cell
transplantation. Solid black line, the low-hepcidin group (\50 ng/mL);
solid gray line, the high-hepcidin group ($50 ng/mL); CI, confidence
interval.Hepcidin production is regulated by at least 3 fac-
tors: iron load [16,17], inflammation [18], and un-
known erythropoietic signals [23-25]. Therefore, the
good predictive value of hepcidin with respect to the
incidence of documented bacterial infection can be
partly explained by the cumulative effect of at least
these 3 factors on bacterial infection. Iron overload in-
creases the level of circulating non-transferrin-bound
iron, which is known to amplify free-radical reactions
in inflammatory or ischemia-related conditions [7,26].
Such reactions could enhance tissue damage such as
mucositis during the conditioning regimen, thereby
allowing bacterial translocation through the damaged
mucosa [27]. In addition, iron is a necessary nutrient
for bacteria and fungus [28]. The association between
hemochromatosis, 1 of the iron overload disorders,
and infection with certain organisms has already
been described [29]. Therefore, the high hepcidin
levels might reflect iron overload status, which has an
adverse effect on bacterial infections. Second, a high
hepcidin level may indicate inflammation because of
a latent bacterial infection that was undetectable
before HSCT, but may surface in posttransplant neu-
tropenic status. Last, a high hepcidin level could reflect
suppressed erythropoiesis, probably because of the
short duration from the last chemotherapy to the start
of the conditioning regimen for transplantation.
Repeated cytotoxic chemotherapy in a short period
may exacerbate tissue damage and increase the risk of
bacterial infection.
Although serum ferritin levels do not necessarily
correlate with the amount of iron load in patients
with inflammation or specific diseases [1,30,31], it is
frequently used and regarded as a indicator of iron
overloading, and several studies have demonstrated
the association between high ferritin levels and treat-
ment-related mortality (TRM) [3,11]. In this cohort,
an elevation of serum ferritin level was not found to
be a significant risk factor for bacterial infection,
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factor even after adjustment for other potential con-
founders. Furthermore, we observed consistent associ-
ation of high hepcidin levels with high risk for
developing bacterial infection when analyses were con-
fined to either the low- or high-ferritin subgroups.
These findings collectively suggest that hepcidin can
be used as a better predictor of documented bacterial
infections than serum ferritin levels.Moreover, various
new techniques to quantify hepcidin-25, such as
a competitive enzyme-linked immunoassay as well as
mass spectrometry-based methods, have been recently
developed [19,25,32,33]. Standardization of those
methods will make it possible to use the serum hepci-
din level as a biomarker in routine clinical practice.
Hepcidin was first isolated and characterized as an
antimicrobial peptide in human blood [12]. In radial
diffusion assays, synthetic hepcidin suppressed the
growth of several strains of Gram-positive bacteria
and some strains of Gram-negative bacteria, but not
of Escherichia coli or Pseudomonas fluorescens. Our find-
ings pertaining to the adverse association of high hep-
cidin levels with bacterial infection indicated that the
bactericidal effect of hepcidin was either considerably
limited in neutropenic settings such as HSCT or was
ineffective on the bacterial organisms observed in our
cohort. Moreover, we observed a significant adverse
effect of hepcidin even after the adjustment for poten-
tial confounders, suggesting that hepcidin itself may
play an unknown biologic role in susceptibility to
bacterial infection, or it may represent an unknown
surrogate marker for predicting bacterial infection.
To answer this issue, the significance of pretransplant
serum hepcidin levels needs to be evaluated in a more
homogeneous group of patients having the same level
of confounders.
We did not detect any adverse effect of high hepci-
din levels on infection-related mortality or OS at 100
days after transplantation, although there was amarked
difference in the incidence of bacterial infection. One
possible explanation for this observation is that bacte-
rial infection of the blood was well managed by prompt
and appropriate treatment with antibiotics in our
transplant centers. However, because the incidence
of early death after HSCT is considerably low, the ef-
fect of bacterial infection on early mortality should be
evaluated in larger cohort studies to gain enough sta-
tistical power for comparison. Alternatively, selective
prophylactic administration of oral antibiotics such
as fluoroquinolones to patients with a high risk of bac-
terial infection may be an effective approach; however,
this approach will be effective only if most of the bac-
terial isolates at the transplant center are sufficiently
sensitive to these prophylactic antibiotics.With regard
to other endpoints, there was no association between
high hepcidin levels and the incidence of CMV infec-
tion. The effect of hepcidin level on the incidence offungal infection could not be evaluated because of
the very low incidences of these conditions in our
cohorts. These effects should also be evaluated in stud-
ies with a larger cohort in the future.
The present study, however, has some limitations.
We cannot exclude the possibility of a pseudonegative
result for bloodstream infection, because broad-spec-
trum antibiotics were administered to all neutropenic
patients at the time of blood culture, regardless of
the results of blood culture. In addition, the retrospec-
tive study design and heterogeneous background of
diseases and transplantation procedures could also
bias the results. Particularly, in the small cohort of
55 patients, the adjustment of HRs by confounders
may be incomplete. In particular, the higher propor-
tion of CB transplants and the high risk of diseases in
the high-hepcidin group may cause bias, although we
found consistently high HRs in the high-hepcidin
group in various stratified categories. Therefore,
larger studies are necessary to confirm our results.
In conclusion, our study revealed that the pretrans-
plant serum hepcidin level was significantly associated
with bacterial infection, particularly bloodstream in-
fection, suggesting that quantification of serum hepci-
din levels could be useful for predicting early bacterial
complications. Prophylactic antibiotic therapy based
on the local sensitivities of common bacterial isolates
can be considered in the patients with high hepcidin
levels who are undergoing allogeneic HSCT. Larger
prospective studies are, however, warranted to confirm
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